{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:12:42Z","timestamp":1789776762745,"version":"4.0.1"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012112","name":"Sobi","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"DOI":"10.1186\/s12969-025-01092-5","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T12:15:09Z","timestamp":1745410509000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Unmet needs and research gaps in Still\u2019s disease across ages: proceedings from a pediatric and adult joint expert panel"],"prefix":"10.1186","volume":"23","author":[{"given":"Claudia","family":"Bracaglia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Minoia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan J.","family":"Vastert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Dagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Ravelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"De Benedetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"issue":"2","key":"1092_CR1","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41584-023-01065-6","volume":"20","author":"P Ruscitti","year":"2024","unstructured":"Ruscitti P, Cantarini L, Nigrovic PA, McGonagle D, Giacomelli R. Recent advances and evolving concepts in Still\u2019s disease. Nat Rev Rheumatol. 2024;20(2):116\u201332.","journal-title":"Nat Rev Rheumatol."},{"issue":"2","key":"1092_CR2","first-page":"150","volume":"45","author":"JR Silva","year":"2020","unstructured":"Silva JR, Brito I. Systemic juvenile idiopathic arthritis versus adult-onset Still\u2019s disease: the pertinence of changing the current classification criteria. Acta Reumatol Port. 2020;45(2):150\u20131.","journal-title":"Acta Reumatol Port."},{"issue":"4","key":"1092_CR3","doi-asserted-by":"publisher","first-page":"e003578","DOI":"10.1136\/rmdopen-2023-003578","volume":"9","author":"A Vitale","year":"2023","unstructured":"Vitale A, Caggiano V, Lopalco G, et al. Still\u2019s disease continuum from childhood to elderly: data from the international AIDA Network Still\u2019s disease registry. RMD Open. 2023;9(4):e003578.","journal-title":"RMD Open."},{"issue":"12","key":"1092_CR4","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1136\/ard-2024-225853","volume":"83","author":"A De Matteis","year":"2024","unstructured":"De Matteis A, Bindoli S, De Benedetti F, Carmona L, Fautrel B, Mitrovic S. Systemic juvenile idiopathic arthritis and adult-onset Still\u2019s disease are the same disease: evidence from systematic reviews and meta-analyses informing the 2023 EULAR\/PReS recommendations for the diagnosis and management of Still\u2019s disease. Ann Rheum Dis. 2024;83(12):1748\u201361.","journal-title":"Ann Rheum Dis."},{"issue":"12","key":"1092_CR5","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1136\/ard-2024-225851","volume":"83","author":"B Fautrel","year":"2024","unstructured":"Fautrel B, Mitrovic S, De Matteis A, et al. EULAR\/PReS recommendations for the diagnosis and management of Still\u2019s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still\u2019s disease. Ann Rheum Dis. 2024;83(12):1614\u201327.","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"1092_CR6","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.rdc.2023.06.007","volume":"49","author":"GS Schulert","year":"2023","unstructured":"Schulert GS, Kessel C. Molecular pathways in the pathogenesis of systemic juvenile idiopathic arthritis. Rheum Dis Clin North Am. 2023;49(4):895\u2013911.","journal-title":"Rheum Dis Clin North Am."},{"issue":"2","key":"1092_CR7","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/art.41107","volume":"72","author":"C Kessel","year":"2020","unstructured":"Kessel C, Hedrich CM, Foell D. Innately adaptive or truly autoimmune: is there something unique about systemic juvenile idiopathic arthritis? Arthritis Rheumatol. 2020;72(2):210\u20139.","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"1092_CR8","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/art.38615","volume":"66","author":"PA Nigrovic","year":"2014","unstructured":"Nigrovic PA. Is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol. 2014;66(6):1405\u201313.","journal-title":"Arthritis Rheumatol."},{"issue":"12","key":"1092_CR9","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1136\/annrheumdis-2019-216040","volume":"78","author":"VE Saper","year":"2019","unstructured":"Saper VE, Chen G, Deutsch GH, et al. Emergent high fatality lung disease in systemic juvenile arthritis. Ann Rheum Dis. 2019;78(12):1722\u201331.","journal-title":"Ann Rheum Dis."},{"issue":"10","key":"1092_CR10","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1093\/rheumatology\/keac027","volume":"61","author":"P Ruscitti","year":"2022","unstructured":"Ruscitti P, Natoli V, Consolaro A, et al. Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still\u2019s disease. Rheumatology (Oxford). 2022;61(10):4124\u20139.","journal-title":"Rheumatology (Oxford)."},{"issue":"2","key":"1092_CR11","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/art.30128","volume":"63","author":"PA Nigrovic","year":"2011","unstructured":"Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63(2):545\u201355.","journal-title":"Arthritis Rheum."},{"issue":"6","key":"1092_CR12","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/art.41612","volume":"73","author":"M Pardeo","year":"2021","unstructured":"Pardeo M, Rossi MN, Pires Marafon D, et al. Early treatment and IL1RN single-nucleotide polymorphisms affect response to anakinra in systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2021;73(6):1053\u201361.","journal-title":"Arthritis Rheumatol."},{"issue":"7","key":"1092_CR13","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/art.40865","volume":"71","author":"NM Ter Haar","year":"2019","unstructured":"Ter Haar NM, van Dijkhuizen EHP, Swart JF, et al. Treatment to target using recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study. Arthritis Rheumatol. 2019;71(7):1163\u201373.","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"1092_CR14","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/art.38296","volume":"66","author":"SJ Vastert","year":"2014","unstructured":"Vastert SJ, de Jager W, Noordman BJ, et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol. 2014;66(4):1034\u201343.","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"1092_CR15","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.semarthrit.2021.06.004","volume":"51","author":"P Efthimiou","year":"2021","unstructured":"Efthimiou P, Kontzias A, Hur P, Rodha K, Ramakrishna GS, Nakasato P. Adult-onset Still\u2019s disease in focus: clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies. Semin Arthritis Rheum. 2021;51(4):858\u201374.","journal-title":"Semin Arthritis Rheum."},{"issue":"4","key":"1092_CR16","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.rdc.2021.06.003","volume":"47","author":"R Erkens","year":"2021","unstructured":"Erkens R, Esteban Y, Towe C, Schulert G, Vastert S. Pathogenesis and treatment of refractory disease courses in systemic juvenile idiopathic arthritis: refractory arthritis, recurrent macrophage activation syndrome and chronic lung disease. Rheum Dis Clin North Am. 2021;47(4):585\u2013606.","journal-title":"Rheum Dis Clin North Am."},{"issue":"1","key":"1092_CR17","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3899\/jrheum.100726","volume":"38","author":"JL Record","year":"2011","unstructured":"Record JL, Beukelman T, Cron RQ. Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series. J Rheumatol. 2011;38(1):180\u20131.","journal-title":"J Rheumatol."},{"issue":"3","key":"1092_CR18","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/00005792-200205000-00003","volume":"81","author":"B Fautrel","year":"2002","unstructured":"Fautrel B, Zing E, Golmard JL, et al. Proposal for a new set of classification criteria for adult-onset still disease. Medicine (Baltimore). 2002;81(3):194\u2013200.","journal-title":"Medicine (Baltimore)."},{"issue":"2","key":"1092_CR19","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390\u20132.","journal-title":"J Rheumatol."},{"issue":"2","key":"1092_CR20","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3899\/jrheum.180168","volume":"46","author":"A Martini","year":"2019","unstructured":"Martini A, Ravelli A, Avcin T, et al. Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trials organization international consensus. J Rheumatol. 2019;46(2):190\u20137.","journal-title":"J Rheumatol."},{"issue":"3","key":"1092_CR21","first-page":"424","volume":"19","author":"M Yamaguchi","year":"1992","unstructured":"Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still\u2019s disease. J Rheumatol. 1992;19(3):424\u201330.","journal-title":"J Rheumatol."},{"issue":"1","key":"1092_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12969-018-0224-2","volume":"16","author":"CH Hinze","year":"2018","unstructured":"Hinze CH, Holzinger D, Lainka E, et al. Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany. Pediatr Rheumatol. 2018;16(1):7.","journal-title":"Pediatr Rheumatol."},{"key":"1092_CR23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2147\/OARRR.S151013","volume":"10","author":"B Lerkvaleekul","year":"2018","unstructured":"Lerkvaleekul B, Vilaiyuk S. Macrophage activation syndrome: early diagnosis is key. Open Access Rheumatol. 2018;10:117\u201328.","journal-title":"Open Access Rheumatol."},{"issue":"5","key":"1092_CR24","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.hoc.2015.06.010","volume":"29","author":"A Ravelli","year":"2015","unstructured":"Ravelli A, Dav\u00ec S, Minoia F, Martini A, Cron RQ. Macrophage activation syndrome. Hematol Oncol Clin North Am. 2015;29(5):927\u201341.","journal-title":"Hematol Oncol Clin North Am."},{"issue":"5","key":"1092_CR25","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrrheum.2015.179","volume":"12","author":"AA Grom","year":"2016","unstructured":"Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. 2016;12(5):259\u201368.","journal-title":"Nat Rev Rheumatol."},{"issue":"9","key":"1092_CR26","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.1136\/annrheumdis-2019-216286","volume":"80","author":"R Wang","year":"2021","unstructured":"Wang R, Li T, Ye S, et al. Application of MS score in macrophage activation syndrome patients associated with adult onset Still\u2019s disease. Ann Rheum Dis. 2021;80(9):e145.","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"1092_CR27","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3390\/jcm11010206","volume":"11","author":"C Javaux","year":"2021","unstructured":"Javaux C, El-Jammal T, Neau PA, et al. Detection and prediction of macrophage activation syndrome in Still\u2019s disease. J Clin Med. 2021;11(1):206.","journal-title":"J Clin Med."},{"issue":"10","key":"1092_CR28","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1136\/annrheumdis-2019-215211","volume":"78","author":"F Minoia","year":"2019","unstructured":"Minoia F, Bovis F, Dav\u00ec S, et al. Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2019;78(10):1357\u201362.","journal-title":"Ann Rheum Dis."},{"issue":"11","key":"1092_CR29","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1002\/art.38802","volume":"66","author":"F Minoia","year":"2014","unstructured":"Minoia F, Dav\u00ec S, Horne A, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol. 2014;66(11):3160\u20139.","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"1092_CR30","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","volume":"48","author":"JI Henter","year":"2007","unstructured":"Henter JI, Horne A, Aric\u00f3 M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124\u201331.","journal-title":"Pediatr Blood Cancer."},{"issue":"1","key":"1092_CR31","doi-asserted-by":"publisher","first-page":"e000161","DOI":"10.1136\/rmdopen-2015-000161","volume":"2","author":"A Ravelli","year":"2016","unstructured":"Ravelli A, Minoia F, Dav\u00ec S, et al. Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. RMD Open. 2016;2(1):e000161.","journal-title":"RMD Open."},{"issue":"3","key":"1092_CR32","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/art.39332","volume":"68","author":"A Ravelli","year":"2016","unstructured":"Ravelli A, Minoia F, Dav\u00ec S, et al. 2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism\/American College of Rheumatology\/Paediatric Rheumatology International Trials Organisation collaborative initiative. Arthritis Rheumatol. 2016;68(3):566\u201376.","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"1092_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00296-018-4114-1","volume":"39","author":"Y Tada","year":"2019","unstructured":"Tada Y, Inokuchi S, Maruyama A, et al. Are the 2016 EULAR\/ACR\/PRINTO classification criteria for macrophage activation syndrome applicable to patients with adult-onset Still\u2019s disease? Rheumatol Int. 2019;39(1):97\u2013104.","journal-title":"Rheumatol Int."},{"issue":"1","key":"1092_CR34","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1136\/annrheumdis-2015-209020","volume":"76","author":"C Bracaglia","year":"2017","unstructured":"Bracaglia C, de Graaf K, Pires Marafon D, et al. Elevated circulating levels of interferon-\u03b3 and interferon-\u03b3-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2017;76(1):166\u201372.","journal-title":"Ann Rheum Dis."},{"issue":"16","key":"1092_CR35","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1182\/blood.2019000936","volume":"135","author":"SW Canna","year":"2020","unstructured":"Canna SW, Marsh RA. Pediatric hemophagocytic lymphohistiocytosis. Blood. 2020;135(16):1332\u201343.","journal-title":"Blood."},{"issue":"13","key":"1092_CR36","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1182\/blood-2017-12-820852","volume":"131","author":"ES Weiss","year":"2018","unstructured":"Weiss ES, Girard-Guyonvarc\u2019h C, Holzinger D, et al. Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome. Blood. 2018;131(13):1442\u201355.","journal-title":"Blood."},{"issue":"8","key":"1092_CR37","doi-asserted-by":"publisher","first-page":"e563","DOI":"10.1016\/S2665-9913(21)00115-6","volume":"3","author":"C Kessel","year":"2021","unstructured":"Kessel C, Fall N, Grom A, et al. Definition and validation of serum biomarkers for optimal differentiation of hyperferritinaemic cytokine storm conditions in children: a retrospective cohort study. Lancet Rheumatol. 2021;3(8):e563-73.","journal-title":"Lancet Rheumatol."},{"issue":"17","key":"1092_CR38","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1182\/blood.2020009499","volume":"137","author":"V Chaturvedi","year":"2021","unstructured":"Chaturvedi V, Marsh RA, Zoref-Lorenz A, et al. T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis. Blood. 2021;137(17):2337\u201346.","journal-title":"Blood."},{"issue":"4","key":"1092_CR39","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1093\/rheumatology\/keab619","volume":"61","author":"A De Matteis","year":"2022","unstructured":"De Matteis A, Bracaglia C, Pires Marafon D, et al. Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort. Rheumatology (Oxford). 2022;61(4):1621\u20139.","journal-title":"Rheumatology (Oxford)."},{"issue":"22","key":"1092_CR40","doi-asserted-by":"publisher","first-page":"e165616","DOI":"10.1172\/JCI165616","volume":"133","author":"Z Huang","year":"2023","unstructured":"Huang Z, Brodeur KE, Chen L, et al. Type I interferon signature and cycling lymphocytes in macrophage activation syndrome. J Clin Invest. 2023;133(22):e165616.","journal-title":"J Clin Invest."},{"issue":"52","key":"1092_CR41","doi-asserted-by":"publisher","first-page":"15970","DOI":"10.1073\/pnas.1520779112","volume":"112","author":"MJ Ombrello","year":"2015","unstructured":"Ombrello MJ, Remmers EF, Tachmazidou I, et al. HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proc Natl Acad Sci U S A. 2015;112(52):15970\u20135.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"1092_CR42","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/art.42656","volume":"76","author":"RGA Erkens","year":"2024","unstructured":"Erkens RGA, Calis JJA, Verwoerd A, et al. Recombinant interleukin-1 receptor antagonist is an effective first-line treatment strategy in new-onset systemic juvenile idiopathic arthritis, irrespective of HLA-DRB1 background and variants. Arthritis Rheumatol. 2024;76(1):119\u201329.","journal-title":"Arthritis Rheumatol."},{"issue":"8","key":"1092_CR43","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1002\/art.40498","volume":"70","author":"VL Arthur","year":"2018","unstructured":"Arthur VL, Shuldiner E, Remmers EF, et al. IL1RN variation influences both disease susceptibility and response to recombinant human interleukin-1 receptor antagonist therapy in systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2018;70(8):1319\u201330.","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"1092_CR44","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/art.41130","volume":"72","author":"C Hinze","year":"2020","unstructured":"Hinze C, Fuehner S, Kessel C, et al. Impact of IL1RN variants on response to interleukin-1 blocking therapy in systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2020;72(3):499\u2013505.","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"1092_CR45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12969-020-0398-2","volume":"18","author":"N Aljaberi","year":"2020","unstructured":"Aljaberi N, Tronconi E, Schulert G, et al. The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis. Pediatr Rheumatol. 2020;18(1):7.","journal-title":"Pediatr Rheumatol."},{"issue":"12","key":"1092_CR46","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1002\/art.24137","volume":"58","author":"H Wittkowski","year":"2008","unstructured":"Wittkowski H, Frosch M, Wulffraat N, et al. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum. 2008;58(12):3924\u201331.","journal-title":"Arthritis Rheum."},{"issue":"12","key":"1092_CR47","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1164\/rccm.201209-1602OC","volume":"187","author":"D Foell","year":"2013","unstructured":"Foell D, Wittkowski H, Kessel C, et al. Proinflammatory S100A12 can activate human monocytes via Toll-like receptor 4. Am J Respir Crit Care Med. 2013;187(12):1324\u201334.","journal-title":"Am J Respir Crit Care Med."},{"issue":"4","key":"1092_CR48","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.jaci.2018.06.027","volume":"142","author":"C Kessel","year":"2018","unstructured":"Kessel C, Fuehner S, Zell J, et al. Calcium and zinc tune autoinflammatory Toll-like receptor 4 signaling by S100A12. J Allergy Clin Immunol. 2018;142(4):1370\u20133.","journal-title":"J Allergy Clin Immunol."},{"issue":"3","key":"1092_CR49","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.clim.2012.11.008","volume":"147","author":"C Kessel","year":"2013","unstructured":"Kessel C, Holzinger D, Foell D. Phagocyte-derived S100 proteins in autoinflammation: putative role in pathogenesis and usefulness as biomarkers. Clin Immunol. 2013;147(3):229\u201341.","journal-title":"Clin Immunol."},{"issue":"5","key":"1092_CR50","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1172\/JCI89867","volume":"128","author":"T Vogl","year":"2018","unstructured":"Vogl T, Stratis A, Wixler V, et al. Autoinhibitory regulation of S100A8\/S100A9 alarmin activity locally restricts sterile inflammation. J Clin Invest. 2018;128(5):1852\u201366.","journal-title":"J Clin Invest."},{"issue":"2","key":"1092_CR51","doi-asserted-by":"publisher","first-page":"e5958","DOI":"10.1590\/1414-431x20165958","volume":"50","author":"Y Xia","year":"2017","unstructured":"Xia Y, Cui P, Li Q, Liang F, Li C, Yang J. Extremely elevated IL-18 levels may help distinguish systemic-onset juvenile idiopathic arthritis from other febrile diseases. Braz J Med Biol Res. 2017;50(2):e5958.","journal-title":"Braz J Med Biol Res."},{"issue":"7","key":"1092_CR52","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1002\/art.40099","volume":"69","author":"C Kessel","year":"2017","unstructured":"Kessel C, Lippitz K, Weinhage T, et al. Proinflammatory cytokine environments can drive interleukin-17 overexpression by \u03b3\/\u03b4 T cells in systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2017;69(7):1480\u201394.","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"1092_CR53","doi-asserted-by":"publisher","first-page":"e132508","DOI":"10.1172\/jci.insight.132508","volume":"5","author":"LA Henderson","year":"2020","unstructured":"Henderson LA, Hoyt KJ, Lee PY, et al. Th17 reprogramming of T cells in systemic juvenile idiopathic arthritis. JCI Insight. 2020;5(6):e132508.","journal-title":"JCI Insight."},{"issue":"5","key":"1092_CR54","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/art.42409","volume":"75","author":"J Kuehn","year":"2023","unstructured":"Kuehn J, Schleifenbaum S, Hendling M, et al. Aberrant naive CD4-positive T cell differentiation in systemic juvenile idiopathic arthritis committed to B cell help. Arthritis Rheumatol. 2023;75(5):826\u201341.","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"1092_CR55","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s10875-023-01642-0","volume":"44","author":"MC Hoffmann","year":"2024","unstructured":"Hoffmann MC, Cavalli G, Fadle N, et al. Autoantibody-mediated depletion of IL-1RA in Still\u2019s disease and potential impact of IL-1 targeting therapies. J Clin Immunol. 2024;44(2):45.","journal-title":"J Clin Immunol."},{"issue":"1","key":"1092_CR56","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1080\/07853890.2022.2095431","volume":"54","author":"WG Ambler","year":"2022","unstructured":"Ambler WG, Nanda K, Onel KB, Shenoi S. Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives. Ann Med. 2022;54(1):1839\u201350.","journal-title":"Ann Med."},{"issue":"2","key":"1092_CR57","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/art.1780300209","volume":"30","author":"JJ Cush","year":"1987","unstructured":"Cush JJ, Medsger TA Jr, Christy WC, Herbert DC, Cooperstein LA. Adult-onset Still\u2019s disease. Clinical course and outcome. Arthritis Rheum. 1987;30(2):186\u201394.","journal-title":"Arthritis Rheum."},{"key":"1092_CR58","doi-asserted-by":"publisher","first-page":"930141","DOI":"10.3389\/fimmu.2022.930141","volume":"13","author":"H Miyazawa","year":"2022","unstructured":"Miyazawa H, Wada T. Immune-mediated inflammatory diseases with chronic excess of serum interleukin-18. Front Immunol. 2022;13:930141.","journal-title":"Front Immunol."},{"issue":"5","key":"1092_CR59","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/acr.21889","volume":"65","author":"Y Kimura","year":"2013","unstructured":"Kimura Y, Weiss JE, Haroldson KL, et al. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2013;65(5):745\u201352.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"11","key":"1092_CR60","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1002\/art.41073","volume":"71","author":"GS Schulert","year":"2019","unstructured":"Schulert GS, Yasin S, Carey B, et al. Systemic juvenile idiopathic arthritis-associated lung disease: characterization and risk factors. Arthritis Rheumatol. 2019;71(11):1943\u201354.","journal-title":"Arthritis Rheumatol."},{"issue":"12","key":"1092_CR61","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.3390\/diagnostics12123095","volume":"12","author":"D Petrongari","year":"2022","unstructured":"Petrongari D, Di Filippo P, Misticoni F, et al. Lung involvement in systemic juvenile idiopathic arthritis: a narrative review. Diagnostics (Basel). 2022;12(12):3095.","journal-title":"Diagnostics (Basel)."},{"issue":"3","key":"1092_CR62","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1136\/annrheumdis-2021-220578","volume":"81","author":"VE Saper","year":"2022","unstructured":"Saper VE, Ombrello MJ, Tremoulet AH, et al. Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles. Ann Rheum Dis. 2022;81(3):406\u201315.","journal-title":"Ann Rheum Dis."},{"issue":"6","key":"1092_CR63","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s40272-023-00593-8","volume":"25","author":"C Towe","year":"2023","unstructured":"Towe C, Grom AA, Schulert GS. Diagnosis and management of the systemic juvenile idiopathic arthritis patient with emerging lung disease. Paediatr Drugs. 2023;25(6):649\u201358.","journal-title":"Paediatr Drugs."},{"issue":"10","key":"1092_CR64","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1002\/acr.25129","volume":"75","author":"H Wobma","year":"2023","unstructured":"Wobma H, Arvila SR, Taylor ML, et al. Incidence and risk factors for eosinophilia and lung disease in biologic-exposed children with systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2023;75(10):2063\u201372.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"21","key":"1092_CR65","doi-asserted-by":"publisher","first-page":"12810","DOI":"10.3390\/ijms232112810","volume":"23","author":"LA Macovei","year":"2022","unstructured":"Macovei LA, Burlui A, Bratoiu I, et al. Adult-onset Still\u2019s disease-a complex disease, a challenging treatment. Int J Mol Sci. 2022;23(21):12810.","journal-title":"Int J Mol Sci."},{"issue":"25","key":"1092_CR66","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385\u201395.","journal-title":"N Engl J Med."},{"issue":"25","key":"1092_CR67","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396\u2013406.","journal-title":"N Engl J Med."},{"issue":"1","key":"1092_CR68","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13075-017-1462-2","volume":"19","author":"G Horneff","year":"2017","unstructured":"Horneff G, Schulz AC, Klotsche J, et al. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry. Arthritis Res Ther. 2017;19(1):256.","journal-title":"Arthritis Res Ther."},{"key":"1092_CR69","first-page":"21","volume":"16","author":"P Galozzi","year":"2022","unstructured":"Galozzi P, Bindoli S, Doria A, Sfriso P. Progress in biological therapies for adult-onset Still\u2019s disease. Biologics. 2022;16:21\u201334.","journal-title":"Biologics."},{"issue":"12","key":"1092_CR70","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1007\/s10067-018-4095-1","volume":"37","author":"HE S\u00f6nmez","year":"2018","unstructured":"S\u00f6nmez HE, Demir S, Bilginer Y, \u00d6zen S. Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature. Clin Rheumatol. 2018;37(12):3329\u201335.","journal-title":"Clin Rheumatol."},{"issue":"2","key":"1092_CR71","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/rheumatology\/keq218","volume":"50","author":"PM Miettunen","year":"2010","unstructured":"Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology. 2010;50(2):417\u20139.","journal-title":"Rheumatology."},{"issue":"6","key":"1092_CR72","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/art.21061","volume":"52","author":"AA Fitzgerald","year":"2005","unstructured":"Fitzgerald AA, LeClercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still\u2019s disease. Arthritis Rheum. 2005;52(6):1794\u2013803.","journal-title":"Arthritis Rheum."},{"issue":"2","key":"1092_CR73","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/art.41103","volume":"72","author":"EM Eloseily","year":"2020","unstructured":"Eloseily EM, Weiser P, Crayne CB, et al. Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 2020;72(2):326\u201334.","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"1092_CR74","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/rheumatology\/kez282","volume":"59","author":"S Yasin","year":"2020","unstructured":"Yasin S, Fall N, Brown RA, et al. IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome. Rheumatology (Oxford). 2020;59(2):361\u20136.","journal-title":"Rheumatology (Oxford)."},{"issue":"11","key":"1092_CR75","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41584-021-00694-z","volume":"17","author":"F De Benedetti","year":"2021","unstructured":"De Benedetti F, Prencipe G, Bracaglia C, Marasco E, Grom AA. Targeting interferon-\u03b3 in hyperinflammation: opportunities and challenges. Nat Rev Rheumatol. 2021;17(11):678\u201391.","journal-title":"Nat Rev Rheumatol."},{"issue":"6","key":"1092_CR76","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1136\/ard-2022-223739","volume":"82","author":"F De Benedetti","year":"2023","unstructured":"De Benedetti F, Grom AA, Brogan PA, et al. Efficacy and safety of emapalumab in macrophage activation syndrome. Ann Rheum Dis. 2023;82(6):857\u201365.","journal-title":"Ann Rheum Dis."},{"key":"1092_CR77","first-page":"79","volume":"3","author":"A Lurati","year":"2005","unstructured":"Lurati A, Teruzzi B, Salmaso A. Macrophage activation syndrome (MAS) during anti-IL-1 receptor therapy (anakinra) in a patient affected by systemic onset idiopathic juvenile arthritis (soJIA): A report and review of the literature. Pediatr Rheumatol. 2005;3:79\u201385.","journal-title":"Pediatr Rheumatol."},{"issue":"2","key":"1092_CR78","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/rheumatology\/kez284","volume":"59","author":"S Yasin","year":"2019","unstructured":"Yasin S, Solomon K, Canna SW, et al. IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome. Rheumatology. 2019;59(2):442\u20135.","journal-title":"Rheumatology."},{"issue":"3","key":"1092_CR79","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1093\/rheumatology\/keae440","volume":"64","author":"R Caorsi","year":"2025","unstructured":"Caorsi R, Bertoni A, Matucci-Cerinic C, et al. Long-term efficacy of MAS825, a bispecific anti-IL1\u03b2and IL-18 monoclonal antibody, in two patients with sJIA and recurrent episodes of macrophage activation syndrome. Rheumatology (Oxford). 2025;64(3):1528\u201333.","journal-title":"Rheumatology (Oxford)."},{"issue":"1","key":"1092_CR80","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10875-022-01353-y","volume":"43","author":"JE Rood","year":"2023","unstructured":"Rood JE, Rezk A, Pogoriler J, et al. Improvement of refractory systemic juvenile idiopathic arthritis-associated lung disease with single-agent blockade of IL-1\u03b2 and IL-18. J Clin Immunol. 2023;43(1):101\u20138.","journal-title":"J Clin Immunol."},{"issue":"2","key":"1092_CR81","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1136\/annrheumdis-2020-216983","volume":"81","author":"B Bader-Meunier","year":"2022","unstructured":"Bader-Meunier B, Hadchouel A, Berteloot L, et al. Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease\u202f: a case report. Ann Rheum Dis. 2022;81(2):e20.","journal-title":"Ann Rheum Dis."},{"issue":"5","key":"1092_CR82","doi-asserted-by":"publisher","first-page":"e20182845","DOI":"10.1542\/peds.2018-2845","volume":"143","author":"Z Huang","year":"2019","unstructured":"Huang Z, Lee PY, Yao X, Zheng S, Li T. Tofacitinib treatment of refractory systemic juvenile idiopathic arthritis. Pediatrics. 2019;143(5):e20182845.","journal-title":"Pediatrics."},{"issue":"7","key":"1092_CR83","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.3390\/jcm12072702","volume":"12","author":"F Zekre","year":"2023","unstructured":"Zekre F, Duncan A, Laurent A, et al. Rescue of PAP-MAS in systemic JIA using Janus kinase inhibitors, case report and systematic review. J Clin Med. 2023;12(7):2702.","journal-title":"J Clin Med."},{"issue":"7","key":"1092_CR84","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1093\/rheumatology\/keac694","volume":"62","author":"Y Fu","year":"2023","unstructured":"Fu Y, Li J, Xu A, Chen J, Wang X, Ye S. Ruxolitinib rescued the macrophage activation syndrome in adult-onset Still\u2019s disease with delayed hypersensitivity reaction to tocilizumab. Rheumatology (Oxford). 2023;62(7):e223\u20135.","journal-title":"Rheumatology (Oxford)."},{"issue":"4","key":"1092_CR85","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1093\/rheumatology\/keac440","volume":"62","author":"L Gillard","year":"2023","unstructured":"Gillard L, Pouchot J, Cohen-Aubart F, et al. JAK inhibitors in difficult-to-treat adult-onset Still\u2019s disease and systemic-onset juvenile idiopathic arthritis. Rheumatology (Oxford). 2023;62(4):1594\u2013604.","journal-title":"Rheumatology (Oxford)."},{"issue":"4","key":"1092_CR86","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.jaci.2017.07.021","volume":"141","author":"G Prencipe","year":"2018","unstructured":"Prencipe G, Caiello I, Pascarella A, et al. Neutralization of IFN-\u03b3 reverts clinical and laboratory features in a mouse model of macrophage activation syndrome. J Allergy Clin Immunol. 2018;141(4):1439\u201349.","journal-title":"J Allergy Clin Immunol."},{"issue":"19","key":"1092_CR87","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","volume":"382","author":"F Locatelli","year":"2020","unstructured":"Locatelli F, Jordan MB, Allen C, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med. 2020;382(19):1811\u201322.","journal-title":"N Engl J Med."},{"key":"1092_CR88","unstructured":"Novimmune. Gamifanttm (emapalumab-lzsg) injection, for intravenous use. US Food and Drug Administration. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761107s000lbl.pdf. Accessed 20 Feb 2024."},{"issue":"Suppl 1","key":"1092_CR89","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12969-023-00868-x","volume":"21","author":"AA Grom","year":"2024","unstructured":"Grom AA, Canna SW, Abu-Arja RF, et al. Part 5: allogeneic HSCT in refractory SJIA with lung disease; recent cases from centers in North America & Europe. Pediatr Rheumatol. 2024;21(Suppl 1):86.","journal-title":"Pediatr Rheumatol."},{"issue":"12","key":"1092_CR90","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.3390\/jcm10122633","volume":"10","author":"S Mitrovic","year":"2021","unstructured":"Mitrovic S, Fautrel B. Clinical phenotypes of adult-onset Still\u2019s disease: new insights from pathophysiology and literature findings. J Clin Med. 2021;10(12):2633.","journal-title":"J Clin Med."},{"key":"1092_CR91","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12969-015-0047-3","volume":"13","author":"N Nirmala","year":"2015","unstructured":"Nirmala N, Brachat A, Feist E, et al. Gene-expression analysis of adult-onset Still\u2019s disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity. Pediatr Rheumatol. 2015;13:50.","journal-title":"Pediatr Rheumatol."},{"issue":"1","key":"1092_CR92","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12969-022-00755-x","volume":"20","author":"G Horneff","year":"2022","unstructured":"Horneff G, Borchert J, Heinrich R, et al. Incidence, prevalence, and comorbidities of juvenile idiopathic arthritis in Germany: a retrospective observational cohort health claims database study. Pediatr Rheumatol. 2022;20(1):100.","journal-title":"Pediatr Rheumatol."},{"issue":"Suppl 1","key":"1092_CR93","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1136\/annrheumdis-2023-eular.2242","volume":"82","author":"C Bracaglia","year":"2023","unstructured":"Bracaglia C, Minoia F, Kessel C, et al. POS0277 Systemic juvenile idiopathic arthritis associated lung disease in Europe. Ann Rheum Dis. 2023;82(Suppl 1):379.","journal-title":"Ann Rheum Dis."},{"key":"1092_CR94","doi-asserted-by":"publisher","unstructured":"\u00a0He T, Ling J, Yang J. Pulmonary involvements in systemic juvenile arthritis [09 June 2020, PREPRINT version 1.0]. Research Square; 2020. https:\/\/doi.org\/10.21203\/rs.3.rs-33776\/v1.","DOI":"10.21203\/rs.3.rs-33776\/v1"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-025-01092-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-025-01092-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-025-01092-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T13:02:31Z","timestamp":1745413351000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-025-01092-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":94,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1092"],"URL":"https:\/\/doi.org\/10.1186\/s12969-025-01092-5","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"3 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CB: Consultant for Sobi and Novartis, and Speaker for GSK. FM: Consultant for Sobi and Novartis. SJV: Speaker for Sobi and Novartis, and unrestricted research grant from Sobi in a public private grant application. CK: Consultant\/Speaker for Sobi and Novartis, and research support from Novartis. LD: Consultant for and honoraria from AbbVie, Alfasigma, Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, GSK, Janssen, Kiniksa Pharmaceuticals, Merk Sharp & Dohme, Mundipharma Pharmaceuticals, Novartis, Pfizer, Roche, Sanofi-Genzyme, Sobi, and Vifor. AR: Consultant for Galapagos and Novartis, and Speaker for Alexion, Sobi, and Novartis. FDB: Consultant for Sobi, Novartis, Sanofi, Elixiron, Apollo, and Kiniksa Pharmaceuticals, and Speaker for Sobi, Sanofi, Novartis, and Fresenius Kabi.\u00a0Angelo Ravelli is\u00a0Co-Editor-in-Chief\u00a0of Pediatric Rheumatology, Christoph Kessel is Senior Editor of the journal, and\u00a0Claudia Bracaglia, Francesca Minoia, Fabrizio de Benedetti, and Baas Vastert are Members of the Editorial Board of the journal. The peer review of this paper was therefore overseen by an independent member of the editorial board and\u00a0the submission was subject to the\u00a0same review process as applied to any other manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}